This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

About INMC 2019

NanoMed MFG Collaborative is a not-for-profit social enterprise focusing on the diffusion and acceleration of nano-based biopharmaceutical innovations and technologies at the intersection of research development and industrialization. We are in the process of developing a research commercialization center for nanomedicines within the vicinity of the Texas Medical Center. Through unique industry partnerships, NanoMed MFG Collaborative is developing a new innovation network to support the growth of this emerging market for patient treatment options.

Our core vision is to promote unlicensed intellectual capital, create startups, and help companies in the space fund their product development, clinical trials, and commercialization pathways. In the short term, the NanoMed MFG Collaborative will create an incubator and accelerator in the nanomedicine and regenerative medicine space. The Innovate Nanomedicine conference will be a platform to help facilitate annual investments for these companies. Our team will help companies develop their network locally in Houston and nationally and develop actionable product development roadmaps, marketing and sales strategies.

NanoMed MFG Collaborative is currently developing a five-year industry analysis report on manufacturing nanotechnologies in medicine. The industry study is being curated to understand how to improve the manufacturability of nanomedicine-based technologies through smart and advanced manufacturing instrumentation and processing. The industry research is reviewing four pillars along translational pipeline including (1) business development, (2) advanced manufacturing technologies, (3) risk assessment and (4) economic impact and public policy. The expectation is this study will disseminate to the industry, NAICS 32541, the benefits in cost reduction utilizing modern manufacturing. NanoMed MFG Collaborative is eliciting the views from the industry innovating within the pharmaceutical ecosystem to identify added-value strategies. If your organization is interested in collaborating and/or endorsing this industry market research, our team welcomes your participation.

 

Clinical nanomedicine categories covered include:

  • Diagnostics
  • Therapeutics
  • Regenerative
  • Drug Delivery
  • Vaccines
  • Biomaterials
  • Toxicology
  • Nanoinformatics
  • MFG in Clinical Trials
    1. Diagnostics
    2. Therapeutics
    3. Regenerative
    4. Drug Delivery
    5. Vaccines
    6. Biomaterials
    7. Toxicology
    8. Nanoinformatics
    9. MFG in Clinical Trials